Targeting Apoptosis in Cancer Therapy

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2020 Mar 24

PMID 32203277

Citations 897

Authors

Benedito A Carneiro

Wafik S El-Deiry

Affiliations

Soon will be listed here.

Abstract

For over three decades, a mainstay and goal of clinical oncology has been the development of therapies promoting the effective elimination of cancer cells by apoptosis. This programmed cell death process is mediated by several signalling pathways (referred to as intrinsic and extrinsic) triggered by multiple factors, including cellular stress, DNA damage and immune surveillance. The interaction of apoptosis pathways with other signalling mechanisms can also affect cell death. The clinical translation of effective pro-apoptotic agents involves drug discovery studies (addressing the bioavailability, stability, tumour penetration, toxicity profile in non-malignant tissues, drug interactions and off-target effects) as well as an understanding of tumour biology (including heterogeneity and evolution of resistant clones). While tumour cell death can result in response to therapy, the selection, growth and dissemination of resistant cells can ultimately be fatal. In this Review, we present the main apoptosis pathways and other signalling pathways that interact with them, and discuss actionable molecular targets, therapeutic agents in clinical translation and known mechanisms of resistance to these agents.

Citing Articles

Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance.

Xiao Y, Hassani M, Moghaddam M, Fazilat A, Ojarudi M, Valilo M Med Oncol. 2025; 42(4):108.

PMID: 40087196 DOI: 10.1007/s12032-025-02675-8.

Zein-sodium caseinate-diosmin nanoparticles as a promising anti-cancer agent with targeted efficacy against A2780 cell line.

Faezi M, Motavalizadehkakhky A, Homayouni Tabrizi M, Dolatabadi S, Es-Haghi A Sci Rep. 2025; 15(1):8762.

PMID: 40082691 PMC: 11906759. DOI: 10.1038/s41598-025-93772-1.

In Vitro and In Silico Cytotoxic Activity of Isocordoin from Against Cancer Cells.

Silva V, Munoz E, Ferreira C, Russo A, Villena J, Montenegro I Int J Mol Sci. 2025; 26(5).

PMID: 40076860 PMC: 11900625. DOI: 10.3390/ijms26052238.

Anastasis and Other Apoptosis-Related Prosurvival Pathways Call for a Paradigm Shift in Oncology: Significance of Deintensification in Treating Solid Tumors.

Mirzayans R Int J Mol Sci. 2025; 26(5).

PMID: 40076508 PMC: 11900100. DOI: 10.3390/ijms26051881.

Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis.

Tong Z, Wang Z, Jiang J, Fu W, Hu S Oncol Lett. 2025; 29(4):207.

PMID: 40070780 PMC: 11894513. DOI: 10.3892/ol.2025.14954.

References

Chen K, Demarco B, Heilig R, Shkarina K, Boettcher A, Farady C . Extrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP3 inflammasome assembly. EMBO J. 2019; 38(10). PMC: 6517827. DOI: 10.15252/embj.2019101638. View

Hart L, El-Deiry W . Cell death: a new Par-4 the TRAIL. Cell. 2009; 138(2):220-2. DOI: 10.1016/j.cell.2009.07.007. View

Jiang C, Lai F, Tay K, Croft A, Rizos H, Becker T . Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 2011; 1:e69. PMC: 3032346. DOI: 10.1038/cddis.2010.48. View

Sarosiek K, Fraser C, Muthalagu N, Bhola P, Chang W, McBrayer S . Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Cancer Cell. 2016; 31(1):142-156. PMC: 5363285. DOI: 10.1016/j.ccell.2016.11.011. View

Sax J, Fei P, Murphy M, Bernhard E, Korsmeyer S, El-Deiry W . BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol. 2002; 4(11):842-9. DOI: 10.1038/ncb866. View

Prabhu V, Madhukar N, Gilvary C, Kline C, Oster S, El-Deiry W . Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res. 2018; 25(7):2305-2313. PMC: 7259201. DOI: 10.1158/1078-0432.CCR-18-2572. View

Baig S, Seevasant I, Mohamad J, Mukheem A, Huri H, Kamarul T . Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?. Cell Death Dis. 2016; 7:e2058. PMC: 4816162. DOI: 10.1038/cddis.2015.275. View

Ledgerwood E, Morison I . Targeting the apoptosome for cancer therapy. Clin Cancer Res. 2009; 15(2):420-4. DOI: 10.1158/1078-0432.CCR-08-1172. View

Jin Z, El-Deiry W . Overview of cell death signaling pathways. Cancer Biol Ther. 2005; 4(2):139-63. DOI: 10.4161/cbt.4.2.1508. View

10.

Xin M, Li R, Xie M, Park D, Owonikoko T, Sica G . Small-molecule Bax agonists for cancer therapy. Nat Commun. 2014; 5:4935. PMC: 4172359. DOI: 10.1038/ncomms5935. View

11.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G . Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019; 380(22):2095-2103. PMC: 11827445. DOI: 10.1056/NEJMoa1900574. View

12.

Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S . Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res. 2005; 3(6):335-43. DOI: 10.1158/1541-7786.MCR-04-0136. View

13.

Blandino G, Di Agostino S . New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37(1):30. PMC: 5815234. DOI: 10.1186/s13046-018-0705-7. View

14.

Ye L, Yuan G, Xu F, Sun Y, Chen Z, Chen M . The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells. Tumour Biol. 2014; 36(5):3447-55. DOI: 10.1007/s13277-014-2980-z. View

15.

Pan R, Hogdal L, Benito J, Bucci D, Han L, Borthakur G . Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2013; 4(3):362-75. PMC: 3975047. DOI: 10.1158/2159-8290.CD-13-0609. View

16.

Shah S, Luke J, Jacene H, Chen T, Giobbie-Hurder A, Ibrahim N . Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018; 28(6):605-610. DOI: 10.1097/CMR.0000000000000509. View

17.

Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko G, Rudka T . OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell. 2006; 126(1):177-89. DOI: 10.1016/j.cell.2006.06.025. View

18.

Parrales A, Iwakuma T . Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol. 2016; 5:288. PMC: 4685147. DOI: 10.3389/fonc.2015.00288. View

19.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

20.

Herbst R, Eckhardt S, Kurzrock R, Ebbinghaus S, ODwyer P, Gordon M . Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010; 28(17):2839-46. DOI: 10.1200/JCO.2009.25.1991. View